Pfizer Inc.
COMBINATION OF A CDK INHIBITOR AND A PIM INHIBITOR

Last updated:

Abstract:

This invention relates to combination therapies comprising a cyclin dependent kinase (CDK) inhibitor, in particular a CDK4/6 inhibitor, and a proviral integration site for Moloney murine leukemia virus (PIM) inhibitor, and associated pharmaceutical compositions, methods of treatment, and uses.

Status:
Application
Type:

Utility

Filling date:

31 Jan 2020

Issue date:

28 Apr 2022